ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV

Autor: Maria Daskou, William Mu, Madhav Sharma, Hariclea Vasilopoulos, Rachel Heymans, Eleni Ritou, Valerie Rezek, Philip Hamid, Athanasios Kossyvakis, Shubhendu Sen Roy, Victor Grijalva, Arnab Chattopadhyay, Scott G. Kitchen, Alan M. Fogelman, Srinivasa T. Reddy, Theodoros Kelesidis
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: PLoS Pathogens, Vol 18, Iss 1 (2022)
Druh dokumentu: article
ISSN: 1553-7366
1553-7374
Popis: Novel therapeutic strategies are needed to attenuate increased systemic and gut inflammation that contribute to morbidity and mortality in chronic HIV infection despite potent antiretroviral therapy (ART). The goal of this study is to use preclinical models of chronic treated HIV to determine whether the antioxidant and anti-inflammatory apoA-I mimetic peptides 6F and 4F attenuate systemic and gut inflammation in chronic HIV. We used two humanized murine models of HIV infection and gut explants from 10 uninfected and 10 HIV infected persons on potent ART, to determine the in vivo and ex vivo impact of apoA-I mimetics on systemic and intestinal inflammation in HIV. When compared to HIV infected humanized mice treated with ART alone, mice on oral apoA-I mimetic peptide 6F with ART had consistently reduced plasma and gut tissue cytokines (TNF-α, IL-6) and chemokines (CX3CL1) that are products of ADAM17 sheddase activity. Oral 6F attenuated gut protein levels of ADAM17 that were increased in HIV-1 infected mice on potent ART compared to uninfected mice. Adding oxidized lipoproteins and endotoxin (LPS) ex vivo to gut explants from HIV infected persons increased levels of ADAM17 in myeloid and intestinal cells, which increased TNF-α and CX3CL1. Both 4F and 6F attenuated these changes. Our preclinical data suggest that apoA-I mimetic peptides provide a novel therapeutic strategy that can target increased protein levels of ADAM17 and its sheddase activity that contribute to intestinal and systemic inflammation in treated HIV. The large repertoire of inflammatory mediators involved in ADAM17 sheddase activity places it as a pivotal orchestrator of several inflammatory pathways associated with morbidity in chronic treated HIV that make it an attractive therapeutic target. Author summary Novel therapeutic strategies are needed to attenuate increased systemic and gut inflammation that contribute to morbidity and mortality in chronic HIV infection despite potent antiviral therapy. In this study we used preclinical models of chronic HIV (humanized mice and gut tissues from HIV infected persons) to determine whether antioxidant and anti-inflammatory agents called apoA-I mimetic peptides could attenuate systemic and gut inflammation in chronic HIV. Our preclinical data suggest that apoA-I mimetic peptides can target increased levels of a protein called ADAM17 and its proinflammatory activity that contributes to systemic and gut inflammation in HIV. The large repertoire of inflammatory mediators involved in ADAM17 sheddase activity places it as a pivotal orchestrator of several inflammatory pathways associated with morbidity in chronic treated HIV that make it an attractive therapeutic target.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje